Gatekeeper function of the RUNX1 transcription factor in acute leukemia

被引:29
作者
Niebuhr, Birte [1 ]
Fischer, Meike [1 ]
Taeger, Maike [1 ]
Carnmenga, Jorg [2 ]
Stocking, Carol [1 ]
机构
[1] Heinrich Pette Inst, D-25051 Hamburg, Germany
[2] Lund Univ, Lund Strateg Ctr Stem Cell Biol & Cell Therapy, SE-221 Lund, Sweden
关键词
leukemia stem cell; core-binding factor; differentiation; self-renewal;
D O I
10.1016/j.bcmd.2007.07.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The RUNX1 gene encodes the alpha subunit of the core binding factor (CBF) and is a common target of genetic mutations in acute leukemia. We propose that RUNX1 is a gatekeeper gene, the disruption of which leads to the exodus of a subset of hematopoietic progenitors with increased self-renewal potential from the normal environmental controls of homeostasis. This pool of "escaped" cells is the target of secondary mutations, accumulating over time to induce the aggressive manifestation of acute leukemia. Evidence from patient and animal studies supports the concept that RUNX1 Mutations are the initiating event in different leukemia subtypes, but also suggests that diverse mechanisms are used to subvert RUNX1 function. One common result is the inhibition of differentiation-but its effect impinges on different lineages and stages of differentiation, depending on the mutation or fusion partner. A number of different approaches have led to the identification of secondary events that lead to the overt acute phase; however, the majority is unknown. Finally, the concept of the "leukemia stern cell" and its therapeutic importance is discussed in light of the RUNX1 gatekeeper function. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 81 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Molecular genetics of acute lymphoblastic leukemia [J].
Armstrong, SA ;
Look, AT .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6306-6315
[3]   AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation [J].
Bäsecke, J ;
Schwieger, M ;
Griesinger, F ;
Schiedlmeier, B ;
Wulf, G ;
Trümper, L ;
Stocking, C .
LEUKEMIA & LYMPHOMA, 2005, 46 (02) :265-272
[4]  
Beghini A, 2004, HAEMATOLOGICA, V89, P920
[5]   The RUNX genes: Gain or loss of function in cancer [J].
Blyth, K ;
Cameron, ER ;
Neil, JC .
NATURE REVIEWS CANCER, 2005, 5 (05) :376-387
[6]   Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) [J].
Boissel, N. ;
Leroy, H. ;
Brethon, B. ;
Philippe, N. ;
de Botton, S. ;
Auvrignon, A. ;
Raffoux, E. ;
Leblanc, T. ;
Thomas, X. ;
Hermine, O. ;
Quesnel, B. ;
Baruchel, A. ;
Leverger, G. ;
Dombret, H. ;
Preudhomme, C. .
LEUKEMIA, 2006, 20 (06) :965-970
[7]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[8]   Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate [J].
Cammenga, J ;
Horn, S ;
Bergholz, U ;
Sommer, G ;
Besmer, P ;
Fiedler, W ;
Stocking, C .
BLOOD, 2005, 106 (12) :3958-3961
[9]   Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML [J].
Cammenga, J .
LEUKEMIA, 2005, 19 (10) :1719-1728
[10]   RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation [J].
Cammenga, Joerg ;
Niebuhr, Birte ;
Horn, Stefan ;
Bergholz, Ulla ;
Putz, Gabriele ;
Buchholz, Frank ;
Loehler, Juergen ;
Stocking, Carol .
CANCER RESEARCH, 2007, 67 (02) :537-545